BrainChip (BRN) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
20 Feb, 2026Executive summary
2024 marked significant innovation in AI, with BrainChip advancing edge AI through Akida IP and proprietary TENNs models, securing commercial wins with major organizations in aerospace, defense, and research sectors.
The company expanded its patent portfolio, strengthened its engineering and executive teams, and established a Scientific Advisory Board.
Entering 2025, the organization is focused on capitalizing on its robust product roadmap and intensifying operational rigor to drive further market adoption and revenue growth.
Financial highlights
Net loss after tax for 2024 was $24.4M, an improvement from $28.9M in 2023.
Revenue increased 72% to $398K from $232K in 2023, though significant growth in license and product revenue was not achieved.
Operating expenses decreased 17% to $23.9M, with R&D expenses up 9% to $7.7M, S&M expenses down 3% to $4.6M, and G&A expenses up 7% to $6.1M.
Share-based payment expense dropped 52% to $5.45M.
Cash and cash equivalents at year-end were $20M, up from $14.3M.
Outlook and guidance
The company expects to further develop the Akida Neuromorphic SoC and continue expanding its edge AI product offerings.
2025 will focus on building on 2024 achievements, targeting more commercial wins and broader technology adoption.
Latest events from BrainChip
- Revenue up 374%, net loss reduced, and $37M raised to accelerate neuromorphic AI growth.BRN
H2 202526 Feb 2026 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 202529 Jan 2026 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 20251 Dec 2025 - A pivotal year with a new product roadmap, higher bookings targets, and focus on shareholder alignment.BRN
AGM 202520 Nov 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation10 Nov 2025 - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation19 Oct 2025 - Revenue soared 859% and net loss narrowed, with new funding and partnerships fueling growth.BRN
H1 202521 Aug 2025 - Customer receipts surged and cash burn improved, supporting ongoing growth and innovation.BRN
Q2 202529 Jul 2025 - Cash position strengthened to US$25.6M, supporting commercialization and product development.BRN
Q3 202413 Jun 2025